US Bancorp
MRSN

US Bancorp’s Mersana Therapeutics MRSN Stock Holding History

US Bancorp’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-647
Closed -$23.1K – 4309
2024
Q4 		$23.1K Hold
647
– – ﹤0.01% 3096
2024
Q3 		$30.6K Buy
+647
New +$28.5K ﹤0.01% 2961
2023
Q3 		– Sell
-2
Closed -$174 – 4074
2023
Q2 		$174 Buy
+2
New +$293 ﹤0.01% 3927
2022
Q4 		– Sell
-2
Closed – – 4231
2022
Q3 		$0 Buy
+2
New +$325 ﹤0.01% 4159
2021
Q1 		– Sell
-2
Closed -$2K – 3931
2020
Q4 		$2K Buy
+2
New +$1.11K ﹤0.01% 3589

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

US Bancorp's MRSN Position: Q1 2025 in Review

US Bancorp sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 647 shares — an estimated $23.1K sold.

US Bancorp first reported a position in MRSN in Q4 2020 and held it in 5 quarters. The position peaked at $30.6K in Q3 2024. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • US Bancorp reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • US Bancorp sold 647 Mersana Therapeutics shares in Q1 2025, an estimated $23.1K.
  • US Bancorp first reported a position in Mersana Therapeutics in Q4 2020 and held it in 5 quarters.
  • US Bancorp's Mersana Therapeutics position peaked at $30.6K in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on US Bancorp's 13F filing for Q1 2025, filed 8 May 2025.